Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Kalaris Therapeutics (NASDAQ:KLRS – Free Report) from a hold rating to a sell rating in a report released on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings raised Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $18.75.

Get Our Latest Research Report on Kalaris Therapeutics

Kalaris Therapeutics Price Performance

Shares of KLRS stock opened at $2.42 on Friday. The company’s fifty day simple moving average is $2.75 and its two-hundred day simple moving average is $5.26. Kalaris Therapeutics has a 52 week low of $1.78 and a 52 week high of $11.88. The stock has a market cap of $57.61 million, a P/E ratio of -1.20 and a beta of 0.47.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. On average, analysts anticipate that Kalaris Therapeutics will post -1.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Sigma Planning Corp bought a new position in shares of Kalaris Therapeutics in the second quarter valued at approximately $41,000. WealthTrust Asset Management LLC bought a new stake in shares of Kalaris Therapeutics in the 1st quarter worth $72,000. Velan Capital Investment Management LP raised its stake in shares of Kalaris Therapeutics by 38.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after buying an additional 7,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Kalaris Therapeutics in the second quarter valued at $122,000. Finally, Stonepine Capital Management LLC bought a new stake in Kalaris Therapeutics in the second quarter worth about $122,597. 66.05% of the stock is owned by institutional investors and hedge funds.

About Kalaris Therapeutics

(Get Free Report)

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines.

See Also

Analyst Recommendations for Kalaris Therapeutics (NASDAQ:KLRS)

Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.